SLC5A2 and Hypomagnesemia: In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors have gainedincreasing attention as potential treatment opportunity for hypomagnesemia.SGLT2 is expressed in the PT, where it is responsible for the reabsorption ofglucose.